Enlivex Therapeutics Ltd. (ENLV) Stock Price & Growth Analysis - Tweevest

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Enlivex Therapeutics Ltd.

ENLV

NASDAQ

Unprofitable

Unprofitable

31M

Biotechnology

Next Earning date - 14 Nov 2024

31M

Biotechnology

Next Earning date - 14 Nov 2024

1.46USD

-0.02 ( -1.32%)

Relative Strenght

7

Volume Buzz

-61%

Earning Acce

Yes

Dist 52w H.

68%

Quote Panel

Updated October 12, 2024

1W -4.58 % 1M -7.01 % 3M 3.55 % 1Y 3.55 %

Key Metrics

Market Cap
31.26M
Shares Outstanding
21.41M
Share in Float
18.76M
Dividende
0

Earning Date
14 Nov 2024
Price Target
1.4604
Average Volume
73865
Beta
1.042

Range
1.15-4.59
Industry
Biotechnology
Website
https://www.enlivex.com
Sector
Healthcare

Fundamentals

N/A

P/E Ratio

0.00x

P/S Ratio

1.02x

P/B Ratio

0.0

Debt/Equity

0.0%

Net Margin

$-1.2

EPS

How ENLV compares to sector?

P/E Ratio

Relative Strength

ENLV

Sector

loading...

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

0

$0.58

-263%

2025-EPS

0

Analyst rating

No Data Available

Last analyst upgrade/downgrade

EF Hutton

initialise

Previous: Not converted

2024-08-27

Now: Buy

Earnings Growth

YoY

Current

Estimates

Q3.22

N/A

-0.31
vs -0.19

Q4.22

N/A

-0.35
vs -0.26

Q1.23

N/A

-0.39
vs -0.45

Q2.23

N/A

-0.37
vs -0.54

Q3.23

N/A

-0.32
vs -0.31

Q4.23

N/A

-0.48
vs -0.35

Q1.24

N/A

NA
vs -0.39

Q2.24

N/A

-0.16
vs -0.37

Q3.24

N/A

-0.18
vs -0.32

Q4.24

N/A

-0.15
vs -0.48

Sales Growth

YoY

Current

Estimates

Q1.22

NA

NA vs NA

Q2.22

NA

NA vs NA

Q3.22

NA

NA vs NA

Q4.22

NA

NA vs NA

Q1.23

NA

NA vs NA

Q2.23

NA

NA vs NA

Q3.23

NA

NA vs NA

Q4.23

NA

NA vs NA

Q1.24

NA

NA vs NA

Q2.24

NA

NA vs NA

Return on Equity

QoQ

Q3.22

-9%

-0.09
vs -0.20

Q4.22

-11%

-0.11
vs -0.09

Q1.23

-15%

-0.15
vs -0.11

Q2.23

-15%

-0.15
vs -0.15

Q3.23

-15%

-0.15
vs -0.15

Q4.23

-30%

-0.30
vs -0.15

Q1.24

-15%

-0.15
vs -0.30

Q2.24

-11%

-0.11
vs -0.15

Institutionnal Ownership

QoQ

Q3.22

22

22
vs 22

NA

Q4.22

24

24
vs 22

9%

Q1.23

20

20
vs 24

-17%

Q2.23

21

21
vs 20

5%

Q3.23

18

18
vs 21

-14%

Q4.23

18

18
vs 18

NA

Q1.24

19

19
vs 18

6%

Q2.24

19

19
vs 19

NA

Earnings Growth

Latest News

ENLV

globenewswire.com

8 hours ago

Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

ENLV

globenewswire.com

8 hours ago

Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis

ENLV

accesswire.com

9 hours ago

GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ENLV

accesswire.com

9 hours ago

Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ENLV

zacks.com

13 hours ago

All You Need to Know About Enlivex Therapeutics (ENLV) Rating Upgrade to Buy

ENLV

globenewswire.com

16 hours ago

Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering

New Feature Coming Soon, Stay Tuned!

Shape

Shape